Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
940
datasets available to search
ShareScore release 0.9.0
Dataset results
940 results for “Sickle”
bT87Q-globin gene therapy reduces sickle hemoglobin production, allowing for ex vivo anti-sickling activity in human erythroid cells
GEO Series GSE148529. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Hydroxyurea stimulates production of pro-inflammatory cytokines in endothelial cells: Relevance to sickle cell disease.
GEO Series GSE11372. Homo sapiens. 45 samples. Type: Expression profiling by array.
Effect of Hydroxyurea Therapy on Growth Parameters in Older Children with Sickle Cell Disease: Low Dose Versus High Dose.
<p>Supplementary Table for a manuscript titled:</p> <p><strong>Effect of Hydroxyurea Therapy on Growth Parameters in Older Children with Sickle Cell Disease: Low Dose Versus High Dose.</strong></p> <p> </p>
A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease
<p><a href="https://viz.stjude.cloud/communityData/PGS_snpLists.xlsx">Polygenic Risk Scores</a> is from the Pain study described below:</p> <p>Recurrent acute pain, or vaso-occlusive pain crisis (VOP), is the most common complication of sickle cell disease and correlates strongly with increased hospital visits and early mortality <a href="https://pubmed.ncbi.nlm.nih.gov/1710777/">PMID: 1710777</a>. While the genetics of VOP in sickle cell patients has been studied (PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29205277/">29205277</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/27883292/">27883292</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/25102390/">25102390</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/30079801/">30079801</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/22925497/">22925497</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/29531649/">29531649</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/29620434/">29620434</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/19468207/">19468207</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/20172753/">20172753</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/22576309/">22576309</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/30031848/">30031848</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/24136375/">24136375</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/27603703/">27603703</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/29559808/">29559808</a>), it is not fully understood.</p> <p>Using WGS, we interrogated the <em>a</em>-thalassemia deletion -<em>a</em>3.7 and 133 candidate risk single nucleotide polymorphisms (SNPs) across an additional 65 genes for association with VOP: 11 SNPs in 3 gene regions associated with fetal hemoglobin (HbF) and 122 additional SNPs in 62 genes previously reported to be associated with pain due to SCD and/or other etiologies. We then constructed unweighted polygenic risk scores (PGSs) by counting the total number of risk alleles per individual across the 11 HbF SNPs (PGSHbF) and the 5 SNPs in COMT (PGSCOMT), where COMT is the gene previously associated with SCD pain (PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29559808/">29559808</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/215537663/">15537663</a>). We also defined a final PGS comprised of these 16 SNPs plus another 5 internally-validated candidate SNPs (PGSHbF+COMT+5snps), which was more strongly associated with acute VOP than any individual variant. Additionally, patients with the highest 5% of scores had 3-fold more pain events than the bottom 5% but were 5 times more likely to be on hydroxyurea, indicating that patients with high scores might benefit from a second drug.</p>
sickle and hammer
A cool thing I did in my free time, what do you think? By the way I'm new to blender, in 3d modeling in general. Source: Objaverse 1.0 / Sketchfab
Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease
ClinicalTrials.gov study NCT01369160. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease Chronic Pain.
ClinicalTrials.gov study NCT07066072. IPD Sharing: Not stated. Countries: 1. Publications: 0.
MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients
ClinicalTrials.gov study NCT03720626. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
ClinicalTrials.gov study NCT04008368. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait
ClinicalTrials.gov study NCT00005782. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, and Quality of Life.
ClinicalTrials.gov study NCT06823219. IPD Sharing: NO. Countries: 1. Publications: 0.
Transfusion Exchanges and Cognition in Sickle Cell Disease
ClinicalTrials.gov study NCT07168447. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Cognitive Rehabilitation in Sickle Cell Disease
ClinicalTrials.gov study NCT01793740. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BEATS 2: Music Therapy in Sickle Cell
ClinicalTrials.gov study NCT03233269. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
ClinicalTrials.gov study NCT00512226. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluating Barriers to Stroke Screening and Prevention in Children With Sickle Cell Disease
ClinicalTrials.gov study NCT03621826. IPD Sharing: NO. Countries: 1. Publications: 0.
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
ClinicalTrials.gov study NCT06662825. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Early Life Exposures Among Children With Sickle Cell Disease
ClinicalTrials.gov study NCT05377372. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Exploratory Study on Global Reflexology in Sickle Cell Disease
ClinicalTrials.gov study NCT06619197. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina
ClinicalTrials.gov study NCT03253211. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.